Meeting
2014 ASCO Annual Meeting
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).
Authors
Hiroshige Yoshioka
Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan
Hiroshige Yoshioka , Tetsuya Mitsudomi , Satoshi Morita , Yasushi Yatabe , Shunichi Negoro , Isamu Okamoto , Takashi Seto , Miyako Satouchi , Hirohito Tada , Tomonori Hirashima , Kazuhiro Asami , Nobuyuki Katakami , Minoru Takada , Kazuhiko Shibata , Shinzoh Kudoh , Eiji Shimizu , Hiroshi Saito , Shinichi Toyooka , Kazuhiko Nakagawa , Masahiro Fukuoka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
000000539
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8117)
DOI
10.1200/jco.2014.32.15_suppl.8117
Abstract #
8117
Poster Bd #
298
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase ΙΙ study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation.
First Author: Shintaro Kanda
Poster
2017 ASCO Annual Meeting
Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.
First Author: Yong Song
Poster
2011 ASCO Annual Meeting
Final overall survival results of NEJ002, a phase 3 trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
First Author: A. Inoue
Poster
2011 ASCO Annual Meeting
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919).
First Author: W. Parulekar